Moving East: The Euro-Lupus Nephritis regimen in Asia

Kidney International

Volumn 89, Issue 1, 2016, Pages 25-27

  Houssiau, Frédéric A ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ASIA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; END STAGE RENAL DISEASE; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; PREDICTION; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; LUPUS NEPHRITIS; UNCERTAINTY;

ASIA; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; UNCERTAINTY;

EID: 84973169012     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.11.003     Document Type: Note

References (9)

1. G.K. Bertsias, M. Tektonidou, Z. Amoura, and et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis Ann Rheum Dis 71 2012 1771 1782
2. B.H. Hahn, M.A. McMahon, A. Wilkinson, and et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Arthritis Care Res (Hoboken) 64 2012 797 808
3. M. Dall'Era, M.G. Cisternas, D.E. Smilek, and et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort Arthritis Rheumatol 67 2015 1305 1313
4. F. Tamirou, B.R. Lauwerys, M. Dall'Era, and et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial Lupus Sci Med 2 2015 e000123 10.1136/lupus-2015-000123
5. M. Rathi, A. Goyal, A. Jaryal, and et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis Kidney Int 89 2016 235 242
6. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, and et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 2002 2121 2131
7. F.A. Houssiau, C. Vasconcelos, D. D'Cruz, and et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis 69 2010 61 64
8. G.B. Appel, G. Contreras, M.A. Dooley, and et al. Mycophenolate mofetil versus cyclosphosphamide for induction treatment of lupus nephritis J Am Soc Nephrol 20 2009 1103 1112
9. D. Wofsy, B. Diamond, and F.A. Houssiau Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America Arthritis Rheumatol 67 2015 1144 1146